Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Importance Non–small cell lung cancer remains the leading cause of cancer death in the
United States. Until the last decade, the 5-year overall survival rate for patients with …

Background Data on patients with COVID-19 who have cancer are lacking. Here we
characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify …

Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

The most recent version of the European Society for Medical Oncology (ESMO) Clinical
Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Primary lung cancer is the most common malignancy after nonmelanocytic skin cancer with
deaths from lung cancer exceeding those from any other type of malignancy worldwide [1] …

In a longitudinal clinical study to compare two groups, the primary end point is often the time
to a specific event (eg, disease progression, death). The hazard ratio estimate is routinely …